NewsBenzingaNovo Nordisk gibt neue retrospektive Real-World-Evidenz zu Typ-2-Diabetes bekannt, die zeigt, dass Semaglutid-Injektion 2 mg mit einem statistisch signifikant um 6 % geringeren Risiko für schwere kardiovaskuläre Ereignisse verbunden war als bei... Novo Nordisk gibt neue retrospektive Real-World-Evidenz zu Typ-2-Diabetes bekannt, die zeigt, dass Semaglutid-Injektion 2 mg mit einem statistisch signifikant um 6 % geringeren Risiko für schwere kardiovaskuläre Ereignisse verbunden war als bei... Benzinga 2026.09.29 10:35 (GMT+0) Open on Benzinga Other news Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up Bank of New York Earnings Preview: What to Expect Oracle Bear Call Spread Could Net 20% in Under Two Months Two stock picks from a money manager who expects small-caps to roar in 2027 Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst
Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up
Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com
Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst
